Corticosteroid binding globulin regulates cortisol pharmacokinetics

HZA106837 was of variable treatment duration (from a minimum of 24 weeks to a maximum of 76 weeks with the majority of patients treated for at least 52 weeks). In HZA106837 patients were randomised to receive either fluticasone furoate/vilanterol 92/22 micrograms [n=1009] or FF 92 micrograms [n=1010] both administered once daily. In HZA106837 the primary endpoint was the time to first severe asthma exacerbation. A severe asthma exacerbation was defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Adjusted mean change from baseline in trough FEV 1 was also evaluated as a secondary endpoint.

Direct intravenous injection:
Use only methylprednisolone sodium succinate.
Reconstitute with provided diluent or add 2 ml of bacteriostatic water (with benzyl alcohol) for injection.
May be administered undiluted.
Administer directly into a vein over 3—15 minutes. Doses >= 2 mg/kg or 250 mg should be given by intermittent infusion (see below), unless the potential benefits of direct IV injection outweigh the potential risks (., life-threatening shock).
 
Intermittent intravenous infusion:
Use only methylprednisolone sodium succinate.
Dilute in D5W, % Sodium Chloride (NS), or D5NS injection. Haze may form upon dilution.
Infuse over 15—60 minutes. Large doses (., >= 500 mg) should be administered over at least 30—60 minutes.

In controlled and uncontrolled clinical trials involving more than 5000 patients treated with ZYFLO, the overall rate of ALT elevation ≥ 3xULN was %. In these trials, one patient developed symptomatic hepatitis with jaundice , which resolved upon discontinuation of therapy. An additional 3 patients with transaminase elevations developed mild hyperbilirubinemia that was less than three times the upper limit of normal. There was no evidence of hypersensitivity or other alternative etiologies for these findings. In subset analyses, females over the age of 65 appeared to be at an increased risk for ALT elevations. Patients with pre-existing transaminase elevations may also be at an increased risk for ALT elevations (see CONTRAINDICATIONS ).

SACCHAROMYCES CEREVISIAE IGG and IGA ANTIBODIES
SALICYLATE, SERUM
SALICYLATE, URINE
SALMONELLA TOTAL ANTIBODY
SCHISTOSOMA IGG ANTIBODY
SCLERODERMA (Scl-70) ANTIBODY
SELENIUM
SELENIUM RBC
SEQUENTIAL SCREEN PART I (Maternal Serum)
SEQUENTIAL SCREEN PART II (MATERNAL SERUM)
SEROTONIN RELEASE ASSAY, LOW MOLECULAR WEIGHT HEPARIN
SEROTONIN RELEASE ASSAY, UNFRACTIONATED HEPARIN
SEROTONIN, BLOOD
SEROTONIN, SERUM (5-HYDROXYTRYPTAMINE)
SEROTONIN, URINE
SERTRALINE
SERUM INTEGRATED SCREEN PART I (MATERNAL SERUM)
SERUM INTEGRATED SCREEN PART II (MATERNAL SERUM)
SEX HORMONE BINDING GLOBULIN
SICKLE CELL SCREEN
SILVER
SILVER, URINE
SIROLIMUS (RAPAMYCIN)
SJOGREN'S ANTIBODIES (SSA/SSB)
SKIN ANTIBODIES
SMITH ANTIBODY (ANTI-SM)
SMOOTH MUSCLE (F-ACTIN) IgG ANTIBODY
SODIUM, URINE
SOLUBLE LIVER ANTIGEN ANTIBODIES
SOLUBLE TRANSFERRIN RECEPTOR (sTfR)
SOMATOMEDIN-C
SOMATOSTATIN
SPERM IgG, IgA ANTIBODIES
SPUTUM CULTURE
STACHYBOTRYS PANEL II
STONE ANALYSIS WITH IMAGE
STONE ANALYSIS WITHOUT IMAGE
STONE RISK DIAGNOSTIC PROFILE
STOOL CULTURE (VIRUS)
STREPTOCOCCAL ANTIBODIES
STREPTOCOCCUS PNEUMONIAE ANTIGEN DETECTION
STREPTOCOCCUS PNEUMONIAE ANTIGENS, URINE
STREPTOCOCCUS PNEUMONIAE IgG ANTIBODIES, 14 SEROTYPES, MAID
STREPTOCOCCUS PNEUMONIAE IGG ANTIBODIES, 23 SEROTYPES
STREPTOLYSIN O ANTIBODIES (ASO)
STREPTOZYME SCREEN WITH REFLEX TO TITER
STRIATED MUSCLE IgG ANTIBODY
STRONGYLOIDES ANTIBODY, IGG, SERUM
SUBOXONE, URINE
SUBOXONE® - FREE, SERUM/PLASMA
SULFATE, URINE
SULFONYLUREA
SUSCEPTIBILITY, AEROBIC BACTERIA, CUSTOM MIC
SUSCEPTIBILITY, AEROBIC BACTERIA, MIC
SYNTHETIC CANNABINOID METABOLITES SCREEN, URINE
SYPHILIS SEROLOGY TESTING

Corticosteroid binding globulin regulates cortisol pharmacokinetics

corticosteroid binding globulin regulates cortisol pharmacokinetics

SACCHAROMYCES CEREVISIAE IGG and IGA ANTIBODIES
SALICYLATE, SERUM
SALICYLATE, URINE
SALMONELLA TOTAL ANTIBODY
SCHISTOSOMA IGG ANTIBODY
SCLERODERMA (Scl-70) ANTIBODY
SELENIUM
SELENIUM RBC
SEQUENTIAL SCREEN PART I (Maternal Serum)
SEQUENTIAL SCREEN PART II (MATERNAL SERUM)
SEROTONIN RELEASE ASSAY, LOW MOLECULAR WEIGHT HEPARIN
SEROTONIN RELEASE ASSAY, UNFRACTIONATED HEPARIN
SEROTONIN, BLOOD
SEROTONIN, SERUM (5-HYDROXYTRYPTAMINE)
SEROTONIN, URINE
SERTRALINE
SERUM INTEGRATED SCREEN PART I (MATERNAL SERUM)
SERUM INTEGRATED SCREEN PART II (MATERNAL SERUM)
SEX HORMONE BINDING GLOBULIN
SICKLE CELL SCREEN
SILVER
SILVER, URINE
SIROLIMUS (RAPAMYCIN)
SJOGREN'S ANTIBODIES (SSA/SSB)
SKIN ANTIBODIES
SMITH ANTIBODY (ANTI-SM)
SMOOTH MUSCLE (F-ACTIN) IgG ANTIBODY
SODIUM, URINE
SOLUBLE LIVER ANTIGEN ANTIBODIES
SOLUBLE TRANSFERRIN RECEPTOR (sTfR)
SOMATOMEDIN-C
SOMATOSTATIN
SPERM IgG, IgA ANTIBODIES
SPUTUM CULTURE
STACHYBOTRYS PANEL II
STONE ANALYSIS WITH IMAGE
STONE ANALYSIS WITHOUT IMAGE
STONE RISK DIAGNOSTIC PROFILE
STOOL CULTURE (VIRUS)
STREPTOCOCCAL ANTIBODIES
STREPTOCOCCUS PNEUMONIAE ANTIGEN DETECTION
STREPTOCOCCUS PNEUMONIAE ANTIGENS, URINE
STREPTOCOCCUS PNEUMONIAE IgG ANTIBODIES, 14 SEROTYPES, MAID
STREPTOCOCCUS PNEUMONIAE IGG ANTIBODIES, 23 SEROTYPES
STREPTOLYSIN O ANTIBODIES (ASO)
STREPTOZYME SCREEN WITH REFLEX TO TITER
STRIATED MUSCLE IgG ANTIBODY
STRONGYLOIDES ANTIBODY, IGG, SERUM
SUBOXONE, URINE
SUBOXONE® - FREE, SERUM/PLASMA
SULFATE, URINE
SULFONYLUREA
SUSCEPTIBILITY, AEROBIC BACTERIA, CUSTOM MIC
SUSCEPTIBILITY, AEROBIC BACTERIA, MIC
SYNTHETIC CANNABINOID METABOLITES SCREEN, URINE
SYPHILIS SEROLOGY TESTING

Media:

corticosteroid binding globulin regulates cortisol pharmacokineticscorticosteroid binding globulin regulates cortisol pharmacokineticscorticosteroid binding globulin regulates cortisol pharmacokineticscorticosteroid binding globulin regulates cortisol pharmacokineticscorticosteroid binding globulin regulates cortisol pharmacokinetics